TY - JOUR
T1 - The occurrence of apparent bilateral aldosterone suppression in adrenal vein sampling for primary aldosteronism
AU - Shibayama, Yui
AU - Wada, Norio
AU - Naruse, Mitsuhide
AU - Kurihara, Isao
AU - Ito, Hiroshi
AU - Yoneda, Takashi
AU - Takeda, Yoshiyu
AU - Umakoshi, Hironobu
AU - Tsuiki, Mika
AU - Ichijo, Takamasa
AU - Fukuda, Hisashi
AU - Katabami, Takuyuki
AU - Yoshimoto, Takanobu
AU - Ogawa, Yoshihiro
AU - Kawashima, Junji
AU - Ohno, Yuichi
AU - Sone, Masakatsu
AU - Fujita, Megumi
AU - Takahashi, Katsutoshi
AU - Shibata, Hirotaka
AU - Kamemura, Kohei
AU - Fujii, Yuichi
AU - Yamamoto, Koichi
AU - Suzuki, Tomoko
PY - 2018/5/1
Y1 - 2018/5/1
N2 - Context: In adrenal venous sampling (AVS) for patients with primary aldosteronism (PA), apparent bilateral aldosterone suppression (ABAS), defined as lower aldosterone/cortisol ratios in the bilateral adrenal veins than that in the inferior vena cava, is occasionally experienced. ABAS is uninterpretable with respect to lateralization of excess aldosterone production.We previously reported that ABAS was not a rare phenomenon and was significantly reduced after adrenocorticotropic hormone (ACTH) administration. Objective: To validate the effects of ACTH administration and adding sampling positions in the left adrenal vein on the prevalence of ABAS in the larger Japan Primary Aldosteronism Study. Patients: The data from 1689 patients with PAwho underwent AVS between January 2006 and October 2016 were studied. All patients in the previous study, the West Japan Adrenal Vein Sampling study, were excluded. Outcome Measurements: The prevalence of ABAS was investigated at two sampling positions in the left adrenal vein, the central vein and the common trunk, without and with ACTH administration. Results: The prevalence of ABAS with ACTH administration was significantly lower than that without ACTH administration [without ACTH vs with ACTH: 79/440 (18.0%) vs 45/591 (7.6%); P < 0.001]. With ACTH administration, the prevalence of ABAS was not different between the sampling position, at the central vein and at the common trunk [33/591 (5.6%) vs 32/591 (5.4%); P = 1.00]. Conclusions: The effectiveness of ACTH administration for the reduction of ABAS in AVS regardless of the sampling position in the left adrenal vein was confirmed in the larger cohort.
AB - Context: In adrenal venous sampling (AVS) for patients with primary aldosteronism (PA), apparent bilateral aldosterone suppression (ABAS), defined as lower aldosterone/cortisol ratios in the bilateral adrenal veins than that in the inferior vena cava, is occasionally experienced. ABAS is uninterpretable with respect to lateralization of excess aldosterone production.We previously reported that ABAS was not a rare phenomenon and was significantly reduced after adrenocorticotropic hormone (ACTH) administration. Objective: To validate the effects of ACTH administration and adding sampling positions in the left adrenal vein on the prevalence of ABAS in the larger Japan Primary Aldosteronism Study. Patients: The data from 1689 patients with PAwho underwent AVS between January 2006 and October 2016 were studied. All patients in the previous study, the West Japan Adrenal Vein Sampling study, were excluded. Outcome Measurements: The prevalence of ABAS was investigated at two sampling positions in the left adrenal vein, the central vein and the common trunk, without and with ACTH administration. Results: The prevalence of ABAS with ACTH administration was significantly lower than that without ACTH administration [without ACTH vs with ACTH: 79/440 (18.0%) vs 45/591 (7.6%); P < 0.001]. With ACTH administration, the prevalence of ABAS was not different between the sampling position, at the central vein and at the common trunk [33/591 (5.6%) vs 32/591 (5.4%); P = 1.00]. Conclusions: The effectiveness of ACTH administration for the reduction of ABAS in AVS regardless of the sampling position in the left adrenal vein was confirmed in the larger cohort.
UR - http://www.scopus.com/inward/record.url?scp=85064233413&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85064233413&partnerID=8YFLogxK
U2 - 10.1210/js.2017-00481
DO - 10.1210/js.2017-00481
M3 - Article
VL - 2
SP - 398
EP - 407
JO - Journal of the Endocrine Society
JF - Journal of the Endocrine Society
SN - 2472-1972
IS - 5
ER -